SubHero Banner

Keytruda® (pembrolizumab) – Expanded indication

January 8, 2020 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Download PDF